搜尋結果
2023
Narwanti, I. ,
Yu, Z. Y. ,
Sethy, B. ,
Lai, M. J. ,
Lee, H. Y. ,
Olena, P. ,
Lee, S. B. &
Liou, J. P. ,
10月 2023 ,
於: European Journal of Medicinal Chemistry. 258 , 115505.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Dephosphorylation
100%
Apoptotic
91%
Antiproliferative
79%
Quinone
75%
Colorectal Neoplasms
63%
Peng, C. M. ,
Wang, S. W. ,
Hwang, Y. L. ,
Sun, W. C. ,
Chiu, L. P. ,
Liu, Y. T. ,
Lai, Y. W. &
Lee, H. Y. ,
4月 28 2023 ,
於: RSC Advances. 13 ,
19 ,
p. 13169-13176 8 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Polymerization
100%
Cyclization
78%
Benzimidazoles
54%
Polymerization Reaction
53%
Antiproliferative
44%
Kumar, M. ,
Gaivin, R. J. ,
Khan, S. ,
Fedorov, Y. ,
Adams, D. J. ,
Zhao, W. ,
Lee, H. Y. ,
Dai, X. ,
Dealwis, C. G. &
Schelling, J. R. ,
7月 31 2023 ,
於: International Journal of Biological Macromolecules. 244 , 125328.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Diabetes Complications
60%
compound 800
24%
Computer Simulation
22%
Inhibitory Concentration 50
21%
Molecule
20%
Chang, C. D. ,
Chao, M. W. ,
Lee, H. Y. ,
Liu, Y. T. ,
Tu, H. J. ,
Lien, S. T. ,
Lin, T. E. ,
Sung, T. Y. ,
Yen, S. C. ,
Huang, S. H. ,
Hsu, K. C. &
Pan, S. L. ,
2023 ,
於: Journal of Enzyme Inhibition and Medicinal Chemistry. 38 ,
1 , 2166039.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Gemcitabine
100%
Growth Inhibition
79%
Pancreatic Neoplasms
63%
Computer Simulation
62%
Protein
27%
2022
Apoptosis Induction
100%
Histone
73%
Antitumor
62%
Safety
58%
Colorectal Neoplasms
54%
Lee, S. B. ,
Chang, T. Y. ,
Lee, N. Z. ,
Yu, Z. Y. ,
Liu, C. Y. &
Lee, H. Y. ,
1月 5 2022 ,
於: European Journal of Medicinal Chemistry. 227 , 113904.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Bisindole
100%
Antineoplastic Agents
58%
indirubin-3'-monoxime
57%
Antineoplastic Agent
54%
Phosphotransferases
47%
Lin, T. E. ,
Sung, L. C. ,
Chao, M. W. ,
Li, M. ,
Zheng, J. H. ,
Sung, T. Y. ,
Hsieh, J. H. ,
Yang, C. R. ,
Lee, H. Y. ,
Cho, E. C. &
Hsu, K. C. ,
2022 ,
於: Journal of Enzyme Inhibition and Medicinal Chemistry. 37 ,
1 ,
p. 226-235 10 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Agammaglobulinaemia Tyrosine Kinase
100%
Tyrosine Kinase Inhibitor
95%
Tyrosine
31%
% Inhibition
12%
B-Cell Leukemia
10%
2021
Mehndiratta, S. ,
Chen, M. C. ,
Chao, Y. H. ,
Lee, C. H. ,
Liou, J. P. ,
Lai, M. J. &
Lee, H. Y. ,
1月 1 2021 ,
於: Journal of Enzyme Inhibition and Medicinal Chemistry. 36 ,
1 ,
p. 74-84 11 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Histone Deacetylases
100%
Apoptotic
98%
A549 Cells
94%
Histone
91%
Antiproliferative
85%
Lee, S. ,
Wang, S. W. ,
Yu, C. L. ,
Tai, H. C. ,
Yen, J. Y. ,
Tuan, Y. L. ,
Wang, H. H. ,
Liu, Y. T. ,
Chen, S. S. &
Lee, H. Y. ,
11月 15 2021 ,
於: Bioorganic and Medicinal Chemistry. 50 , 116454.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Hydroxamic Acids
100%
Histone Deacetylase 2
99%
Phenylureas
92%
Vascular Endothelial Growth Factor Receptor-2
76%
Hydroxamic Acid
74%
Cho, E. C. ,
Liu, C. Y. ,
Tang, D. W. &
Lee, H. Y. ,
12月 2021 ,
於: Journal of Enzyme Inhibition and Medicinal Chemistry. 36 ,
1 ,
p. 1387-1401 15 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
HCT116 Cells
100%
Histone Deacetylase Inhibitors
90%
16-8 compound
87%
Structure-Activity Relationship
66%
Protein Isoforms
31%
2020
Fang, Y-C. ,
Chan, L. ,
Liou, J-P. ,
Tu, Y-K. ,
Lai, M-J. ,
Chen, C-I. ,
Vidyanti, A. N. ,
Lee, H-Y. &
Hu, C-J. ,
6月 1 2020 ,
於: Journal of Cellular and Molecular Medicine. 24 ,
12 ,
p. 6966-6977 12 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Histone Deacetylase Inhibitors
100%
Brain-Derived Neurotrophic Factor
90%
Acetylation
89%
Histones
64%
Oxygen
60%
Kaur, N. ,
Fang, Y. C. ,
Lee, H. Y. ,
Singh, A. ,
Nepali, K. ,
Lin, M. H. ,
Yeh, T. K. ,
Lai, M. J. ,
Chan, L. ,
Tu, Y. K. ,
Banerjee, S. ,
Hu, C. J. &
Liou, J. P. ,
2月 1 2020 ,
於: European Journal of Medicinal Chemistry. 187 , 111915.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Azepines
100%
Azepine
76%
Histone
60%
Protective
46%
Cognitive Dysfunction
46%
Wang, S. W. ,
Lin, M. H. ,
Hsu, F. C. ,
Chen, M. C. ,
Liou, J. P. ,
Liu, Y. T. ,
Chen, S. S. &
Lee, H. Y. ,
2月 1 2020 ,
於: Bioorganic and Medicinal Chemistry. 28 ,
3 ,
p. 115250 115250.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Antiproliferative
100%
Protein Isoforms
80%
HCT116 Cells
64%
Ether
55%
A549 Cells
55%
2019
Lai, M. J. ,
Ojha, R. ,
Lin, M. H. ,
Liu, Y. M. ,
Lee, H. Y. ,
Lin, T. E. ,
Hsu, K. C. ,
Chang, C. Y. ,
Chen, M. C. ,
Nepali, K. ,
Chang, J. Y. &
Liou, J. P. ,
1月 15 2019 ,
於: European Journal of Medicinal Chemistry. 162 ,
p. 612-630 19 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
indoline
100%
Benzamides
91%
Histone Deacetylases
63%
Tubulin
58%
Histone
58%
Misko, T. A. ,
Liu, Y. T. ,
Harris, M. E. ,
Oleinick, N. L. ,
Pink, J. ,
Lee, H. Y. &
Dealwis, C. G. ,
1月 1 2019 ,
於: Journal of Enzyme Inhibition and Medicinal Chemistry. 34 ,
1 ,
p. 438-450 13 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Hydrazones
100%
Ribonucleotide
80%
Antimetabolite
47%
Hydrazone
32%
Pancreatic Neoplasms
24%
2018
Lee, H. Y. ,
Nepali, K. ,
Huang, F. I. ,
Chang, C. Y. ,
Lai, M. J. ,
Li, Y. H. ,
Huang, H. L. ,
Yang, C. R. &
Liou, J. P. ,
2月 8 2018 ,
於: Journal of Medicinal Chemistry. 61 ,
3 ,
p. 905-917 13 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Quinolines
100%
Histone Deacetylase 6
94%
Histone Deacetylase Inhibitors
68%
Histone
62%
Multiple Myeloma
57%
Lee, H. Y. ,
Fan, S. J. ,
Huang, F. I. ,
Chao, H. Y. ,
Hsu, K. C. ,
Lin, T. E. ,
Yeh, T. K. ,
Lai, M. J. ,
Li, Y. H. ,
Huang, H. L. ,
Yang, C. R. &
Liou, J. P. ,
8月 23 2018 ,
於: Journal of Medicinal Chemistry. 61 ,
16 ,
p. 7087-7102 16 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Histone Deacetylase 6
100%
tau Proteins
77%
Histone Deacetylase Inhibitors
72%
Histone
66%
Hydroxamic Acids
49%
Wu, Y. W. ,
Hsu, K. C. ,
Lee, H. Y. ,
Huang, T. C. ,
Lin, T. E. ,
Chen, Y. L. ,
Sung, T. Y. ,
Liou, J. P. ,
Hwang-Verslues, W. W. ,
Pan, S. L. &
HuangFu, W. C. ,
3月 13 2018 ,
於: Frontiers in Pharmacology. 9 ,
MAR , 205.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Tubulin Modulators
100%
In Vitro Techniques
26%
Tubulin
26%
Histone Deacetylase 6
19%
Neoplasms
19%
Nepali, K. ,
Kumar, S. ,
Huang, H. L. ,
Kuo, F. C. ,
Lee, C. H. ,
Kuo, C. C. ,
Yeh, T. K. ,
Li, Y. H. ,
Chang, J. Y. ,
Liou, J. P. &
Lee, H. Y. ,
1月 1 2018 ,
於: Organic and Biomolecular Chemistry. 16 ,
25 ,
p. 4734 1 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Dione
100%
HSP90 Heat-Shock Proteins
86%
Tubulin
70%
Antineoplastic Agents
62%
Antineoplastic Agent
58%
2017
Lee, H-Y. ,
Lee, J. F. ,
Kumar, S. ,
Wu, Y. W. ,
HuangFu, W-C. ,
Lai, M-J. ,
Li, Y-H. ,
Huang, H. L. ,
Kuo, F. C. ,
Hsiao, C. J. ,
Cheng, C. C. ,
Yang, C. R. &
Liou, J-P. ,
1月 5 2017 ,
於: European Journal of Medicinal Chemistry. 125 ,
p. 1268-1278 11 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Histone Deacetylases
100%
Hydroxamic Acids
92%
Tubulin
92%
Histone
91%
Antitumor
79%
Chao, M. W. ,
Huang, H. L. ,
HuangFu, W. C. ,
Hsu, K. C. ,
Liu, Y. M. ,
Wu, Y. W. ,
Lin, C. F. ,
Chen, Y. L. ,
Lai, M. J. ,
Lee, H. Y. ,
Liou, J. P. ,
Teng, C. M. &
Yang, C. R. ,
2017 ,
於: Oncotarget. 8 ,
17 ,
p. 27772-27785 14 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
quinoline
100%
Leukemia
42%
Glycoproteins
29%
Pharmaceutical Preparations
28%
Neoplasms
22%
Nepali, K. ,
Lee, H-Y. ,
Lai, M-J. ,
Ojha, R. ,
Wu, T. Y. ,
Wu, G. X. ,
Chen, M-C. &
Liou, J-P. ,
2月 15 2017 ,
於: European Journal of Medicinal Chemistry. 127 ,
p. 115-127 13 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Tubastatin A
100%
Carbolines
78%
tubastatin A
60%
Hydroxamic Acid
58%
Histone Deacetylases
55%
oxyresveratrol 2-O-glucopyranoside
100%
2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside
74%
Oxyresveratrol
69%
Wittig Olefination
56%
Stilbenes
55%
2016
Lee, H. Y. ,
Chang, C. Y. ,
Su, C. J. ,
Huang, H. L. ,
Mehndiratta, S. ,
Chao, Y. H. ,
Hsu, C. M. ,
Kumar, S. ,
Sung, T. Y. ,
Huang, Y. Z. ,
Li, Y. H. ,
Yang, C. R. &
Liou, J. P. ,
10月 21 2016 ,
於: European Journal of Medicinal Chemistry. 122 ,
p. 92-101 10 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
quinoline
100%
50 Percent Growth Inhibition
94%
Histone Deacetylases
81%
Histone
75%
Acetylation
70%
Lee, H. Y. ,
Kumar, S. ,
Lin, T. C. &
Liou, J. P. ,
4月 22 2016 ,
於: Journal of Natural Products. 79 ,
4 ,
p. 1170-1173 4 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
denbinobin
100%
phenanthrene
73%
Cyclization
69%
Stilbenes
65%
Decarboxylation
64%
2015
Liu, Y-M. ,
Lee, H. Y. ,
Chen, C-H. ,
Lee, C-H. ,
Wang, L-T. ,
Pan, S. L. ,
Lai, M-J. ,
Yeh, T-K. &
Liou, J. P. ,
1月 2015 ,
於: European Journal of Medicinal Chemistry. 89 ,
p. 320-330 11 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
1,2,3,4-tetrahydroquinoline
100%
Vorinostat
92%
Inhibition of Growth
69%
PC-3 Cells
65%
Histone Deacetylase Inhibitors
62%
Nepali, K. ,
Kumar, S. ,
Huang, H. L. ,
Kuo, F. C. ,
Lee, C. H. ,
Kuo, C. C. ,
Yeh, T. K. ,
Li, Y. H. ,
Chang, J. Y. ,
Liou, J. P. &
Lee, H. Y. ,
2015 ,
於: Organic and Biomolecular Chemistry. 14 ,
2 ,
p. 716-723 8 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Dione
100%
quinoline
93%
HSP90 Heat-Shock Proteins
86%
Methoxy Group
72%
Tubulin
70%
Lee, H. Y. ,
Chang, C-Y. ,
Lai, M-J. ,
Chuang, H-Y. ,
Kuo, C-C. ,
Chang, C-Y. ,
Chang, J-Y. &
Liou, J. P. ,
7月 23 2015 ,
於: Bioorganic and Medicinal Chemistry. 23 ,
15 ,
p. 4230-4236 7 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Antivascular
100%
Vascular Targeting Agent
95%
Antimitotic
79%
Antimitotic Agents
77%
KB Cells
75%
Huang, H-L. ,
Peng, C-Y. ,
Lai, M-J. ,
Chen, C-H. ,
Lee, H. Y. ,
Wang, J-C. ,
Liou, J. P. ,
Pan, S. L. &
Teng, C-M. ,
2015 ,
於: Oncotarget. 6 ,
7 ,
p. 4976-4991 16 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide
100%
Histone Deacetylase Inhibitors
49%
B-Cell Lymphoma
44%
Human Activities
42%
Growth
21%
Lai, M-J. ,
Lee, H. Y. ,
Chuang, H-Y. ,
Chang, L-H. ,
Tsai, A-C. ,
Chen, M. C. ,
Huang, H-L. ,
Wu, Y-W. ,
Teng, C-M. ,
Pan, S. L. ,
Liu, Y-M. ,
Mehndiratta, S. &
Liou, J. P. ,
8月 27 2015 ,
於: Journal of Medicinal Chemistry. 58 ,
16 ,
p. 6549-6558 10 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
benzenesulfonamide
100%
STAT3 Transcription Factor
69%
Tubulin
61%
Phosphorylation
39%
50 Percent Growth Inhibition
38%
Liu, Y-M. ,
Lee, H. Y. ,
Lai, M-J. ,
Pan, S. L. ,
Huang, H-L. ,
Kuo, F-C. ,
Chen, M. C. &
Liou, J. P. ,
8月 17 2015 ,
於: Organic and Biomolecular Chemistry. 13 ,
40 ,
p. 10226-10235 10 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Histone Deacetylase 6
100%
Apoptosis Induction
90%
HCT116 Cells
79%
Histone Deacetylase Inhibitors
72%
inhibitors
71%
2014
Wang, C-Y. ,
Liou, J. P. ,
Tsai, A-C. ,
Lai, M-J. ,
Liu, Y-M. ,
Lee, H. Y. ,
Wang, J-C. ,
Pan, S. L. &
Teng, C-M. ,
2014 ,
於: Oncotarget. 5 ,
20 ,
p. 9838-9850 13 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
3-(1-(3,4-dimethoxybenzenesulfonyl)-1H-indol-5-yl)-N-hydroxyacrylamide
100%
Tissue Inhibitor of Metalloproteinase-3
57%
Up-Regulation
28%
Neoplasms
12%
Cell Cycle Resting Phase
7%
Chang, C. Y. ,
Chuang, H. Y. ,
Lee, H. Y. ,
Yeh, T. K. ,
Kuo, C. C. ,
Chang, C. Y. ,
Chang, J. Y. &
Liou, J. P. ,
4月 22 2014 ,
於: European Journal of Medicinal Chemistry. 77 ,
p. 306-314 9 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Benzophenones
100%
Vascular Targeting Agent
95%
fosbretabulin
89%
Antimitotic
79%
Antimitotic Agents
77%
Lee, H. Y. ,
Tsai, A. C. ,
Chen, M. C. ,
Shen, P. J. ,
Cheng, Y. C. ,
Kuo, C. C. ,
Pan, S. L. ,
Liu, Y. M. ,
Liu, J. F. ,
Yeh, T. K. ,
Wang, J. C. ,
Chang, C. Y. ,
Chang, J. Y. &
Liou, J. P. ,
5月 22 2014 ,
於: Journal of Medicinal Chemistry. 57 ,
10 ,
p. 4009-4022 14 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Histone Deacetylase 6
100%
HCT116 Cells
79%
Histone
66%
7-azaindole dimer
64%
Antiproliferative
61%
Mehndiratta, S. ,
Chiang, Y-F. ,
Lai, M-J. ,
Lee, H. Y. ,
Chen, M. C. ,
Kuo, C-C. ,
Chang, C-Y. ,
Chang, J-Y. &
Liou, J. P. ,
9月 1 2014 ,
於: Bioorganic and Medicinal Chemistry. 22 ,
17 ,
p. 4917-4923 7 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
indoline
100%
Vascular Targeting Agent
96%
benzenesulfonamide
95%
Antimitotic
80%
Antimitotic Agents
78%
Yang, C. R. ,
Shih, K. S. ,
Liou, J. P. ,
Wu, Y. W. ,
Hsieh, I. N. ,
Lee, H. Y. ,
Lin, T. C. &
Wang, J. H. ,
10月 22 2014 ,
於: Journal of Molecular Medicine. 92 ,
11 ,
p. 1147-1158 12 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
denbinobin
100%
Synoviocytes
62%
Anti-Inflammatory Agent
58%
MicroRNA
56%
Vascular Cell Adhesion Molecule-1
53%
Lee, H. Y. ,
Wang, L. T. ,
Li, Y. H. ,
Pan, S. L. ,
Chen, Y. L. ,
Teng, C. M. &
Liou, J. P. ,
11月 28 2014 ,
於: Organic and Biomolecular Chemistry. 12 ,
44 ,
p. 8966-8976 11 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
indoline
100%
3-(7-amino-1-(4-methoxyphenylsulfonyl)indolin-5-yl)-N-hydroxyacrylamide
70%
Indoline
68%
Histone Deacetylases
63%
Histone
58%
Mehndiratta, S. ,
Hsieh, Y. L. ,
Liu, Y. M. ,
Wang, A. W. ,
Lee, H. Y. ,
Liang, L. Y. ,
Kumar, S. ,
Teng, C. M. ,
Yang, C. R. &
Liou, J. P. ,
10月 6 2014 ,
於: European Journal of Medicinal Chemistry. 85 ,
p. 468-479 12 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
indole
100%
Histone Deacetylase Inhibitors
89%
Histone
82%
Cell Viability
76%
Antiinflammatory
73%
Hsieh, I-N. ,
Liou, J. P. ,
Lee, H. Y. ,
Lai, M-J. ,
Li, Y-H. &
Yang, C-R. ,
4月 2014 ,
於: Cell Death and Disease. 5 ,
4 , e1166.
研究成果: 雜誌貢獻 › 文章 › 同行評審
3-(1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide
100%
Histone Deacetylase Inhibitors
48%
Arthritis
36%
Pharmacokinetics
31%
Vorinostat
16%
Liu, Y. M. ,
Chen, H. L. ,
Lee, H. Y. &
Liou, J. P. ,
1月 2014 ,
於: Expert Opinion on Therapeutic Patents. 24 ,
1 ,
p. 69-88 20 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Tubulin Modulators
100%
Microtubules
59%
Vinca Alkaloid
31%
Spindle Apparatus
30%
Taxane
29%
2013
Lee, H. Y. ,
Yang, C-R. ,
Lai, M-J. ,
Huang, H-L. ,
Hsieh, Y-L. ,
Liu, Y-M. ,
Yeh, T-K. ,
Li, Y-H. ,
Mehndiratta, S. ,
Teng, C-M. &
Liou, J. P. ,
7月 2013 ,
於: ChemBioChem. 14 ,
10 ,
p. 1248-1254 7 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
indoline
100%
Indoline
68%
Histone Deacetylase Inhibitors
64%
Histone
58%
3-(1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide
43%
Lee, H. Y. ,
Pan, S. L. ,
Su, M-C. ,
Liu, Y-M. ,
Kuo, C-C. ,
Chang, Y-T. ,
Wu, J-S. ,
Nien, C-Y. ,
Mehndiratta, S. ,
Chang, C-Y. ,
Wu, S-Y. ,
Lai, M-J. ,
Chang, J-Y. &
Liou, J. P. ,
2013 ,
於: Journal of Medicinal Chemistry. 56 ,
20 ,
p. 8008-8018 11 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
6-azaindole
100%
7-(2-furanyl)-1-(4-methoxybenzenesulfonyl)-6-azaindole
54%
Tubulin
45%
ABT751
44%
Antiproliferative
42%
Lee, H. Y. ,
Yang, C-R. ,
Lai, M-J. ,
Huang, H-L. ,
Hsieh, Y-L. ,
Liu, Y-M. ,
Yeh, T-K. ,
Li, Y-H. ,
Mehndiratta, S. ,
Teng, C-M. &
Liou, J. P. ,
7月 2013 ,
於: ChemBioChem. 14 ,
10 ,
p. 1150 1 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
3-(1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide
100%
indoline
76%
Indoline
52%
Carrageenan
49%
Histone Deacetylase Inhibitors
48%
2012
Huang, H-L. ,
Lee, H. Y. ,
Tsai, A-C. ,
Peng, C-Y. ,
Lai, M-J. ,
Wang, J-C. ,
Pan, S. L. ,
Teng, C-M. &
Liou, J. P. ,
8月 22 2012 ,
於: PLoS ONE. 7 ,
8 , e43645.
研究成果: 雜誌貢獻 › 文章 › 同行評審
3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide
100%
histone deacetylase
58%
HCT116 Cells
55%
colorectal neoplasms
52%
Histone Deacetylase Inhibitors
49%
Lee, H. Y. ,
Lee, L. W. ,
Nien, C. Y. ,
Kuo, C. C. ,
Lin, P. Y. ,
Chang, C. Y. ,
Chang, J. Y. &
Liou, J. P. ,
2012 ,
於: Organic and Biomolecular Chemistry. 10 ,
48 ,
p. 9593-9600 8 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Rosenmund-Von Braun Cyanation
100%
indium(III) hydroxide
87%
colchicine
87%
Colchicine
65%
Suzuki Reaction
61%
Lai, M. J. ,
Huang, H. L. ,
Pan, S. L. ,
Liu, Y. M. ,
Peng, C. Y. ,
Lee, H. Y. ,
Yeh, T. K. ,
Huang, P. H. ,
Teng, C. M. ,
Chen, C. S. ,
Chuang, H. Y. &
Liou, J. P. ,
4月 26 2012 ,
於: Journal of Medicinal Chemistry. 55 ,
8 ,
p. 3777-3791 15 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Indoles
100%
50 Percent Growth Inhibition
84%
Histone Deacetylase Inhibitors
73%
Histone
67%
Isoenzymes
62%
2011
Chuang, H-Y. ,
Chang, J-Y. ,
Lai, M-J. ,
Kuo, C-C. ,
Lee, H. Y. ,
Hsieh, H-P. ,
Chen, Y-J. ,
Chen, L-T. ,
Pan, W-Y. &
Liou, J. P. ,
3月 7 2011 ,
於: ChemMedChem. 6 ,
3 ,
p. 450-456 7 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Tubulin Modulators
100%
benzophenone
67%
Benzophenone
65%
Inhibitory Concentration 50
55%
Colchicine
39%
Lee, H. Y. ,
Chang, J. Y. ,
Nien, C. Y. ,
Kuo, C. C. ,
Shih, K. H. ,
Wu, C. H. ,
Chang, C. Y. ,
Lai, W. Y. &
Liou, J. P. ,
12月 22 2011 ,
於: Journal of Medicinal Chemistry. 54 ,
24 ,
p. 8517-8525 9 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
6-methoxyquinoline
100%
Tubulin Modulators
75%
Antiproliferative
46%
Sulfones
45%
Sulfone
44%
Lee, H. Y. ,
Chang, J-Y. ,
Chang, L-Y. ,
Lai, W-Y. ,
Lai, M-J. ,
Shih, K-H. ,
Kuo, C-C. ,
Chang, C-Y. &
Liou, J. P. ,
5月 7 2011 ,
於: Organic and Biomolecular Chemistry. 9 ,
9 ,
p. 3154-3157 4 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Vascular Targeting Agent
100%
fosbretabulin
93%
Tubulin Modulators
92%
Antimitotic
83%
Antimitotic Agents
81%
Lai, M-J. ,
Chang, J-Y. ,
Lee, H. Y. ,
Kuo, C-C. ,
Lin, M. H. ,
Hsieh, H-P. ,
Chang, C-Y. ,
Wu, J-S. ,
Wu, S-Y. ,
Shey, K-S. &
Liou, J. P. ,
9月 2011 ,
於: European Journal of Medicinal Chemistry. 46 ,
9 ,
p. 3623-3629 7 p. 研究成果: 雜誌貢獻 › 文章 › 同行評審
Indoles
100%
Colchicine
80%
combretastatin A-1
66%
Antineoplastic Agents
59%
Antineoplastic Agent
55%